Development and Evaluation of Advanced Insulin Delivery Systems for Improved Glycemic Control
Abstract
The human and financial cost of the global diabetes epidemic is tremendous, which is supported by comorbidities caused by the prolonged hyperglycemia. Although the landmark trials have demonstrated that tight glycemic control is the way to avoid complications, it is extremely difficult to do it with the traditional insulin treatment through multiple daily injections and using regular pumps. These are reactive open-loop systems that are highly mentally and cognitively taxing (diabetes distress) and are constrained by the risk of hypoglycemia leading to most people falling below targets. The development of highly sophisticated insulin delivery systems, especially closed-loop technology that is hybrid is a breakthrough. They combine an insulin pump, a control algorithm, and continuous glucose monitoring to produce an automated biofeedback loop. Such an active intervention can produce a greater glycemic outcome, better time-in-range and less hypoglycemia, and significantly ease the psychological load of daily management. Despite the challenges that are posed by the high initial cost and the fact that these systems require user involvement, these systems are beneficial in terms of cost-effectiveness in the long term since they help to avoid very costly complications. The future of diabetes care is characterized by constant evolution into fully automated systems, faster insulins and individually tailored algorithms. In the end, progressive delivery systems not only treat the physiological, psychological and economic aspects of diabetes but also provide a pivotal way of reducing the burden of diabetes in the world but also enabling people to live freer and more healthy lives.